BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy

International Journal of Cancer

Volumn 126, Issue 5, 2010, Pages 1216-1225

  Yin, Xiaoying ^a,b   Zhang, Hong ^b   Lundgren, Karen ^b   Wilson, Lynn ^b   Burrows, Francis ^b   Shores, Carol G ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b BIOGEN   (United States)

Author keywords

Chemoradiation; Head and neck squamous cell carcinoma; Hsp90 inhibitor; Radiosensitizer; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; BIIB 021; HEAT SHOCK PROTEIN 90 INHIBITOR; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG STRUCTURE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; THERAPY EFFECT; TUMOR XENOGRAFT;

ADENINE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MICE, NUDE; PYRIDINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 74049091229     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24815     Document Type: Article

References (33)

1. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-98.
2. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
3. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
4. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001;20:7453-63.
5. Russell J, Tofilon P. Radiation-induced activation of nuclear factor kappaB involves selective degradation of plasma membrane-associated I(kappa)B(alpha). Mol Biol Cell 2002;13:3431-40.
6. Morimoto RI, Kline MP, Bimston DN, Cotto JJ. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem 1997;32:17-29.
7. Richter K, Muschler P, Hainzl O, Buchner J. Coordinated ATP hydrolysis by the Hsp90 dimer. J Biol Chem 2001;276:33689-96.
8. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 2003;228:111-33.
9. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-99.
10. Pirollo KF, Hao Z, Rait A, Ho CW, Chang EH. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Commun 1997;230:196-201.
11. Gupta AK, Bakanauskas VJ, Cerniglia GJ, Cheng Y, Bernhard EJ, Muschel RJ, McKenna WG. The ras radiation resistant pathway. Cancer Res 2001;61:4278-82.
12. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhance radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999;59:1347-55.
13. Yin X, Zhang H, Burrows F, Zhang L, Shores CG. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2005;11:3889-96.
14. Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer Res 2004;10:8077-84.
15. Russel JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 2003;9:3749-55.
16. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24.
17. Sausville E, Tomaszewski J, Ivy P. Clinical development of 17-allylamino,17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377-83.
18. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2003;2:131-38.
19. Zhang L, Boehm MF, Siead Z. Process for preparing 17-allyl amino geldanamycin (17-AAG) and other ansamycins. US Patent Application WO03026571, 3 April 2003.
20. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002;8:885-92.
21. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a noval target for cancer therapy. Ann Oncol 2003;14:1169-76.
22. Sheridan MT, O'Dwyer T, Seymour CB, Mothersill CE. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 1997;5:180-6.
23. Tanno S, Yanagawa N, Habiro A, Koizumi K, Nakano Y, Osanai M, Mizukami Y, Okumura T, Testa JR, Kohgo Y. Serine/ threonine kinase Akt is frequently activated in human bile duct cancer and is associated with increased radiao-resistance. Cancer Res 2004;64:3486-90.
24. Piro K, Hao Z, Rait A, Ho C, Chang E. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Commun 1997;230:196-201.
25. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999;42:260-6.
26. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:S55-S61.
27. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N. 17-Allylamino-17 demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu. Clin Cancer Res 2002;8:986-93.
28. Zhang H, Yang YC, Zhang L, Fan J, Chung D, Choi D, Grecko R, Timony G, Karjian P, Boehm M, Burrows F. Dimeric ansamycins-a new class of antitumor Hsp90 modulators with prolonged inhibitory activity. Int J Cancer 2007;120:918-26.
29. Machida H, Matsumoto Y, Shirai M, Kubota N. Galdanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol 2003;79:973-80.
30. Matsumoto Y, Machida H, Kubota N. Preferential sensitization of tumor cells to radiation by heat shock protein 90 geldanamycin. J Radiat Res 2005;46:215-21.
31. Machida H, Nakajima S, Shikano N, Nishio J, Okada S, Asayama M, Shirai M, Kubota N. Heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis. Cancer Sci 2005;96:911-17.
32. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003;63:8984-95.
33. Zhang H, Neely L, Lundgren K, Yang Y-C, Burrows F. BIIB021, a synthetic Hsp90 inhibitor, is active against 17-AAG-resistant tumor lines. Int J Cancer, in press.